New drug targets hidden heart risk in early trial

NCT ID NCT03626662

Completed Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a single dose of an investigational drug called AMG 890 in 79 adults with high levels of lipoprotein(a), a genetic risk factor for heart disease. The main goal was to check safety and how the drug moves through the body. Researchers measured side effects and drug levels in the blood to prepare for future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIOVASCULAR DISEASE

Contacts and locations

Locations

Clinical Medical and Analytical eXellence CMAX

Adelaide, South Australia, 5000, Australia
Excel Medical Clinical Trials

Boca Raton, Florida, 33434, United States
Jacksonville Center for Clinical Research

Jacksonville, Florida, 32216, United States
Linear Clinical Research Limited

Nedlands, Western Australia, 6009, Australia
Medpace Inc

Cincinnati, Ohio, 45227, United States
New York University

New York, New York, 10016, United States
Orange County Research Center

Tustin, California, 92780, United States
QPS Miami Research Associates

South Miami, Florida, 33143, United States
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.